CL04177
preclinicaldrug program · high · Mon Oct 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a precision peptide-based therapy for cancers and chronic diseases involving cells with impaired p53 signaling, including solid tumors and hematological malignancies.
Lead peptide therapeutic candidate designed to selectively eliminate impaired-p53/scarred cancer cells.
Optimized lead development candidate being progressed toward clinical development/clinical trials.
Public material states Cleara optimized CL04177 and CL04183 and that these candidates can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans.